Application Nr Approved Date Route Status External Links
ANDA075317 2004-12-20 Oral RX Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Terazosin Capsules Are Indicated For The Treatment Of Symptomatic Benign Prostatic Hyperplasia (bph). There Is A Rapid Response, With Approximately 70% Of Patients Experiencing An Increase In Urinary Flow And Improvement In Symptoms Of Bph When Treated With Terazosin Capsules. The Long-Term Effects Of Terazosin Capsules On The Incidence Of Surgery, Acute Urinary Obstruction Or Other Complications Of Bph Are Yet To Be Determined. Terazosin Capsules Are Also Indicated For The Treatment Of Hypertension. Terazosin Capsules Can Be Used Alone Or In Combination With Other Antihypertensive Agents Such As Diuretics Or Beta-Adrenergic Blocking Agents.

All Formulated Excipients (3 Total)

Name Structure Kind Function Status
1. Silicon Dioxide SILICON DIOXIDE Unresolved AC-Anticaking agent , MISC-Miscellaneous , STAB-Stabilizer GRAS-Generally recognized as safe.
2. Lactose Monohydrate LACTOSE MONOHYDRATE Molecular
3. Magnesium Stearate MAGNESIUM STEARATE Molecular AF-Antifoaming (or defoaming) agent , MISC-Miscellaneous REG-Food additives for which a petition has been filed and a regulation issued.

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Terazosin Hydrochloride TERAZOSIN HYDROCHLORIDE ZINC95616599